Limits...
Overcoming tumor immune evasion with an unique arbovirus.

Lyday B, Chen T, Kesari S, Minev B - J Transl Med (2015)

Bottom Line: Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms.Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock.While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells.

View Article: PubMed Central - PubMed

Affiliation: PrimeVax, LLC, Garden Grove, USA. bruce.lyday@primevax.com.

ABSTRACT
Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms. Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock. While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells. The premise of using multiple mechanisms of action in synergy with a decline in the ability of the tumor cells to employ resistance methods suggests the potential of this combination approach in cancer immunotherapy.

No MeSH data available.


Related in: MedlinePlus

Course of Dengue Fever, Markers, Grading, and Symptoms. (A) Laboratory diagnostic options in a patient with suspected dengue infection, (B) Progression from Dengue Fever to Dengue hemorrhagic fever (DHF) and (C) Timeline and course of clinical signs and symptoms of Dengue.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4307212&req=5

Fig3: Course of Dengue Fever, Markers, Grading, and Symptoms. (A) Laboratory diagnostic options in a patient with suspected dengue infection, (B) Progression from Dengue Fever to Dengue hemorrhagic fever (DHF) and (C) Timeline and course of clinical signs and symptoms of Dengue.

Mentions: The virus infects white blood cells of monocyte/macrophage/dendritic cell lineage [35,36] (Figure 2). The infected cells produce interferons, interleukins, and other factors which mediate both specific and non-specific immune responses, including high fever, capillary permeability, rash, joint pain, and elevations of hepatic transferase enzymes [1,22,35,37] (Table 1 and Figure 3).Table 1


Overcoming tumor immune evasion with an unique arbovirus.

Lyday B, Chen T, Kesari S, Minev B - J Transl Med (2015)

Course of Dengue Fever, Markers, Grading, and Symptoms. (A) Laboratory diagnostic options in a patient with suspected dengue infection, (B) Progression from Dengue Fever to Dengue hemorrhagic fever (DHF) and (C) Timeline and course of clinical signs and symptoms of Dengue.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4307212&req=5

Fig3: Course of Dengue Fever, Markers, Grading, and Symptoms. (A) Laboratory diagnostic options in a patient with suspected dengue infection, (B) Progression from Dengue Fever to Dengue hemorrhagic fever (DHF) and (C) Timeline and course of clinical signs and symptoms of Dengue.
Mentions: The virus infects white blood cells of monocyte/macrophage/dendritic cell lineage [35,36] (Figure 2). The infected cells produce interferons, interleukins, and other factors which mediate both specific and non-specific immune responses, including high fever, capillary permeability, rash, joint pain, and elevations of hepatic transferase enzymes [1,22,35,37] (Table 1 and Figure 3).Table 1

Bottom Line: Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms.Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock.While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells.

View Article: PubMed Central - PubMed

Affiliation: PrimeVax, LLC, Garden Grove, USA. bruce.lyday@primevax.com.

ABSTRACT
Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms. Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock. While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells. The premise of using multiple mechanisms of action in synergy with a decline in the ability of the tumor cells to employ resistance methods suggests the potential of this combination approach in cancer immunotherapy.

No MeSH data available.


Related in: MedlinePlus